SuperworthJasper Therapeutics shares outstanding JSPR
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 28.7M
- On a year earlier
- +87.1%
- more shares
Jasper Therapeutics had 28.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 87.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 28.7M | +91% |
| FY2024 | 15M | +36% |
| FY2023 | 11M | +201% |
| FY2022 | 3.7M | +267% |
| FY2020 | 1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 28.7M | +87% | |
| Q1 FY26 | 28.7M | +91% | |
| Q4 FY25 | 28.7M | +91% | |
| Q3 FY25 | 16.6M | +11% | |
| Q2 FY25 | 15.3M | +2% | |
| Q1 FY25 | 15M | +13% | |
| Q4 FY24 | 15M | +36% | |
| Q3 FY24 | 15M | +37% | |
| Q2 FY24 | 15M | +37% | |
| Q1 FY24 | 13.3M | +52% | |
| Q4 FY23 | 11M | +201% | |
| Q3 FY23 | 11M | +200% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Jasper Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.